TCRT is a clinical-stage anti-cancer cell therapy company headquartered in Houston, USA. It develops TCR-T cell therapies that target shared neoantigens such as KRAS and TP53, which are frequently found in patient tumors.

Its core platform is the non-viral "Sleeping Beauty" transposon technology, which aims to reduce manufacturing costs and time compared with conventional lentivirus-based cell therapies. The TCR-T Library Phase 1/2 trial being conducted at MD Anderson Cancer Center is the company's flagship asset, and it has continued non-clinical and technical validation through a CRADA collaboration with the US National Cancer Institute (NCI).

How does it make money?

Alaunos is a clinical-stage biotech with virtually no revenue, so metrics such as the sales growth rate of -50.0% are of limited significance. Company value is determined not by product sales but by clinical results and the ability to raise capital.

📐 Market Cap and Company Scale

The market cap is $3.0M, roughly About 0% of Samsung Electronics' market cap. The company has 1 people employees.

With a market cap of $3.0M, this is a micro-cap biotech stock. It is about About 0% the size of Samsung Electronics' market cap, and because trading volume and float are extremely small, short-term share-price volatility can be unusually extreme.

📈 Alaunos Therapeutics Outlook and Share-Price Trend

Company value depends heavily on the efficacy and safety data from the TCR-T Library Phase 1/2 trial, validation of the Sleeping Beauty platform, and progress in pipeline expansion, including the newly added obesity program. As is typical of clinical-stage biotechs, losses continue to mount, so $-1.95 and -185.9% are of limited use at this stage of the business. The frequency of capital raises and the cash burn rate are the key valuation variables.

⚔️ Core Strengths and Risks

TCRT has a differentiated technology platform in non-viral TCR-T, but as a clinical-stage micro-cap biotech, financing, clinical, and dilution risks weigh heavily on the stock.

Representative comparables in solid-tumor TCR-T include Adaptimmune Therapeutics (ADAP) and Immunocore (IMCR), while in autologous cell therapy, Iovance (IOVA, TIL therapy) is also frequently cited. In the broader cell-therapy space, including CAR-T, the global comparables include Gilead's Kite, Novartis (NVS), and BMS (BMY), while on the non-viral gene-editing side, Intellia (NTLA) and Beam Therapeutics (BEAM) are grouped together under the "next-generation cell and gene therapy" theme.

✅ Investor Checkpoints

TCRT is a clinical-stage micro-cap biotech whose volatility is very high around every clinical and financing event. Before investing, review the following.

Given the nature of clinical-stage biotech, a single clinical result or financing announcement can move the share price by tens of percent in either direction. Share dilution from new issuances and listing maintenance requirements should also be monitored on an ongoing basis.

TCRT can be an option for investors seeking concentrated exposure to the differentiated non-viral TCR-T technology theme, but position sizing that fully accounts for continued losses, dilution, and clinical-failure risk is essential. The safer approach is to track clinical milestones and cash flow together.

Check Alaunos Therapeutics' real-time quotes, technical indicators, and peer comparisons at a glance on US Stock Today's real-time dashboard.